浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Cost-utility analysis of abemaciclib， palbociclib and ribociclib as first-line treatment in hormone receptor-positive advanced breast cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 16, Pages: 2002-2008(2024)
- 作者机构：
1.中国药科大学国际医药商学院，南京 211198
2.中国药科大学药物经济学评价研究中心，南京 211198
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.16.11
CLC： R956Published：30 August 2024，
Received：05 May 2024，
Revised：10 July 2024，
- 稿件说明：
扫 描 看 全 文
李梦媛,管欣,嵇欣悦等.阿贝西利、哌柏西利和瑞波西利一线治疗激素受体阳性晚期乳腺癌的成本-效用分析 Δ[J].中国药房,2024,35(16):2002-2008.
LI Mengyuan,GUAN Xin,JI Xinyue,et al.Cost-utility analysis of abemaciclib， palbociclib and ribociclib as first-line treatment in hormone receptor-positive advanced breast cancer[J].ZHONGGUO YAOFANG,2024,35(16):2002-2008.
李梦媛,管欣,嵇欣悦等.阿贝西利、哌柏西利和瑞波西利一线治疗激素受体阳性晚期乳腺癌的成本-效用分析 Δ[J].中国药房,2024,35(16):2002-2008. DOI： 10.6039/j.issn.1001-0408.2024.16.11.
LI Mengyuan,GUAN Xin,JI Xinyue,et al.Cost-utility analysis of abemaciclib， palbociclib and ribociclib as first-line treatment in hormone receptor-positive advanced breast cancer[J].ZHONGGUO YAOFANG,2024,35(16):2002-2008. DOI： 10.6039/j.issn.1001-0408.2024.16.11.
摘要
目的
2
从中国医疗卫生体系角度分析阿贝西利、哌柏西利和瑞波西利联用芳香化酶抑制剂（AI）一线治疗激素受体阳性（HR+）晚期乳腺癌的经济性。
方法
2
采用分区生存模型对HR+晚期乳腺癌患者20年的疾病进程进行模拟，模拟周期为4周，模型产出为总成本和质量调整生命年（QALY），以5%的贴现率对成本和效果进行贴现。通过系统检索相关临床试验进行网状Meta分析，获取阿贝西利、哌柏西利、瑞波西利联合AI的疗效参数，以MONALEESA-2试验安慰剂组的生存曲线为基础进行生存拟合和外推。计算3种治疗方案的增量成本-效果比（ICER）和增量净货币效益（INMB）以评估其经济性，意愿支付阈值为3倍我国2023年人均国内生产总值（GDP）；采用单因素敏感性分析和概率敏感性分析检测各个参数对结果的影响以及增量分析结果的稳健性。
结果
2
经过20年的模拟，与哌柏西利+AI方案相比，瑞波西利+AI方案的ICER为58 558.38元/QALY，INMB为62 988.20元；与瑞波西利+AI方案相比，阿贝西利+AI方案的ICER为264 928.34元/QALY，INMB为344.84元。单因素敏感性分析显示，阿贝西利+AI方案对比瑞波西利+AI方案的增量分析结果不稳健。概率敏感性分析证实，当阈值为1～3倍我国2023年人均GDP时，瑞波西利+AI方案成为最经济方案的概率最高。
结论
2
当阈值为1～3倍我国2023年人均GDP时，瑞波西利+AI方案一线治疗中国HR+晚期乳腺癌患者，较阿贝西利+AI方案和哌柏西利+AI方案更可能成为最经济的方案。
Abstract
OBJECTIVE
2
To analyze the cost-effectiveness of abemaciclib， palbociclib and ribociclib combined with aromatase inhibitors （AI） in first-line treatment of hormone receptor-positive （HR+） advanced breast cancer from the perspective of Chinese medical system.
METHODS
2
The 20-year disease course of the patients was simulated by the partitioned survival model， and the simulation period was determined to be 4 weeks， the model output was the total cost and quality-adjusted life year （QALY）， the cost and effect were discounted at a discount rate of 5%. A network meta-analysis was constructed by systematically searching relevant clinical trials to obtain the efficacy parameters of abemaciclib， palbociclib and ribociclib combined with AI. Survival fitting and extrapolation were performed based on the survival curve of the placebo group in MONALEESA-2 trial. Cost-effectiveness was assessed by incremental cost-effectiveness ratio （ICER） and incremental net monetary benefit （INMB）， with a willingness-to-pay threshold of 3 times China’s per capita gross domestic product （GDP） in 2023； one-way sensitivity analysis and probability sensitivity analysis were used to detect the influence of parameters on the results and the robustness of the incremental analysis results.
RESULTS
2
In the 20-year simulation， compared with palbociclib+AI scheme， the ICER of ribociclib+AI scheme was 58 558.38 yuan/QALY and the INMB was 62 988.20 yuan. Compared with ribociclib+AI scheme， the ICER of abemaciclib+AI scheme was 264 928.34 yuan/QALY and the INMB was 344.84 yuan. One-way sensitivity analysis showed that the incremental analysis results of abemaciclib+AI scheme compared to ribociclib+AI scheme were not robust. Probabilistic sensitivity analysis confirmed that the probability of ribociclib+AI scheme becoming the most economical was the highest when the threshold was 1-3 times China’s per capita GDP in 2023.
CONCLUSIONS
2
Ribociclib+AI scheme is more likely to be the most economical first-line treatment than abemaciclib+AI scheme and palbociclib+AI scheme in Chinese patients with HR+ advanced breast cancer when threshold is 1-3 times China’s per capita GDP in 2023.
关键词
晚期乳腺癌激素受体阳性阿贝西利哌柏西利瑞波西利分区生存模型成本-效用分析增量净货币收益
Keywords
hormone receptor-positiveabemaciclibpalbociclibribociclibpartitioned survival modelcost-utility analysisincremental net monetary benefit
references
HAN B F，ZHENG R S，ZENG H M，et al. Cancer incidence and mortality in China，2022[J]. J Natl Cancer Cent，2024，4（1）：47-53.
王乐，岳馨培，石菊芳，等. 我国既往二十年乳腺癌经济负担研究[J]. 中国慢性病预防与控制，2017，25（2）：143-146.
WANG L，YUE X P，SHI J F，et al. Study on the economic burden of breast cancer in China in the past twenty years[J]. Chin J Prev Contr Chronic Dis，2017，25（2）：143-146.
郭晓雷，孙建东，马吉祥，等. 山东省恶性肿瘤经济负担分析[J]. 中国公共卫生，2010，26（7）：813-816.
GUO X L，SUN J D，MA J X，et al. Economic burden of malignant neoplasms in Shandong Province[J]. Chin J Public Health，2010，26（7）：813-816.
KOHLER B A，SHERMAN R L，HOWLADER N，et al. Annual report to the nation on the status of cancer，1975-2011，featuring incidence of breast cancer subtypes by race/ethnicity，poverty，and state[J]. J Natl Cancer Inst，2015，107（6）：djv048.
SHERR C J，ROBERTS J M. CDK inhibitors：positive and negative regulators of G1-phase progression[J]. Genes Dev，1999，13（12）：1501-1512.
KLEIN M E，KOVATCHEVA M，DAVIS L E，et al. CDK4/6 inhibitors：the mechanism of action may not be as simple as once thought[J]. Cancer Cell，2018，34（1）：9-20.
LIU Y Y，WU J Y，JI Z Q，et al. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2- metastatic or advanced breast cancer patients：a network meta-analysis[J]. BMC Cancer，2023，23（1）：816.
PIEZZO M，CHIODINI P，RIEMMA M，et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer：a systematic review and meta-analysis[J]. Int J Mol Sci，2020，21（17）：6400.
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南2023[M]. 北京：人民卫生出版社，2023：101-109.
Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology（CSCO） breast cancer diagnosis and treatment guideline 2023[M]. Beijing：People’s Medical Publishing House，2023：101-109.
刘国恩. 中国药物经济学评价指南 2020[M]. 北京：中国市场出版，2020：1-8.
LIU G E. guidelines for pharmaceutical economics evaluation in China 2020[M]. Beijing：China Market Press，2020：1-8.
JOHNSTON S，MARTIN M，LEO A D，et al. MONARCH 3 final PFS：a randomized study of abemacic-lib as initial therapy for advanced breast cancer[J]. NPJ Breast Cancer，2019，5：5.
GOETZ M P，TOI M，HUOBER J，et al. LBA15 MONARCH 3：interim overall survival（OS） results of abemaciclib plus a nonsteroidal aromatase inhibitor（NSAI） in patients（PTS） with HR+，HER2- advanced breast cancer（ABC）[J]. Ann Oncol，2022，33：S1384.
ZHANG Q Y，SUN T，YIN Y M，et al. MONARCH plus：abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer：the multinational rando-mized phase Ⅲ study[J]. Ther Adv Med Oncol，2020，12：1758835920963925.
FINN R S，CROWN J P，LANG I，et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive，HER2-negative，advanced breast cancer（PALOMA-1/TRIO-18）：a randomised phase 2 study[J]. Lancet Oncol，2015，16（1）：25-35.
FINN R S，BOER K，BONDARENKO I，et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer（PALOMA-1，TRIO-18）[J]. Breast Cancer Res Treat，2020，183（2）：419-428.
RUGO H S，FINN R S，DIÉRAS V，et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up[J]. Breast Cancer Res Treat，2019，174（3）：719-729.
XU B H，HU X C，LI W，et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer：primary results from PALOMA-4[J]. Eur J Cancer，2022，175：236-245.
HORTOBAGYI G N，STEMMER S M，BURRIS H A，et al. Updated results from MONALEESA-2，a phase Ⅲ trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive，HER2-negative advanced breast cancer[J]. Ann Oncol，2019，30（11）：1842.
HORTOBAGYI G N，STEMMER S M，BURRIS H A， et al. Overall survival with ribociclib plus letrozole in advanced breast cancer[J]. N Engl J Med，2022，386（10）：942-950.
GUYOT P，ADES A E，OUWENS M J，et al. Enhanced secondary analysis of survival data：reconstructing the data from published Kaplan-Meier survival curves[J]. BMC Med Res Methodol，2012，12：9.
WIKSTEN A，HAWKINS N，PIEPHO H P，et al. Nonproportional hazards in network meta-analysis：efficient stra-tegies for model building and analysis[J]. Value Health，2020，23（7）：918-927.
ROYSTON P，PARMAR M K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data，with application to prognostic modelling and estimation of treatment effects[J]. Stat Med，2002，21（15）：2175-2197.
GOETZ M P，TOI M，CAMPONE M，et al. MONARCH 3：abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol，2017，35（32）：3638-3646.
YANG J，ZHAO B，LING X L，et al. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer：a multicenter real-world study in the northwest of China[J]. BMC Cancer，2023，23（1）：103.
国家肿瘤质控中心乳腺癌专家委员会，北京乳腺病防治学会健康管理专业委员会. 中国乳腺癌随诊随访与健康管理指南：2022版[J]. 中华肿瘤杂志，2022，44（1）：1-28.
Breast Cancer Expert Committee of National Cancer Qua-lity Control Center，Health Management Professional Committee of Beijing Breast Disease Prevention and Control Society. Comprehensive management guideline for breast cancer follow-up and healthcare：2022 edition[J].Chin J Oncol，2022，44（1）：1-28.
北京市海淀区人民政府. 医疗服务价格查询[EB/OL].（2019-05-25）[2024-04-22]. https：//zyk.bjhd.gov.cn/sjkf/wsyl/201905/t20190515_4318860.shtmlhttps://zyk.bjhd.gov.cn/sjkf/wsyl/201905/t20190515_4318860.shtml.
Haidian District People’s Government of Beijing. Medical service price inquiry [EB/OL].（2019-05-25）[2024-04-22]. https：//zyk.bjhd.gov.cn/sjkf/wsyl/201905/t20190515_4318860.shtmlhttps://zyk.bjhd.gov.cn/sjkf/wsyl/201905/t20190515_4318860.shtml.
YANG J P，HAN J Q，TIAN M L，et al. Cost-effectiveness of ribociclib for hormone receptor-positive HER2-negative advanced breast cancer[J]. Cancer Manag Res，2020，12：12905-12913.
WU B，LI T，CAI J，et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy[J]. BMC Cancer，2014，14：984.
DRANITSARIS G，YU B，KING J，et al. Nab-paclitaxel，docetaxel，or solvent-based paclitaxel in metastatic breast cancer：a cost-utility analysis from a Chinese health care perspective[J]. Clinicoecon Outcomes Res，2015，7：249-256.
WU B，DONG B J，XU Y J，et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma：a cost-effectiveness analysis in a health resource-limited setting[J]. PLoS One，2012，7（3）：e32530.
LUO X，ZHOU Z，ZENG X H，et al. Cost-effectiveness of ensartinib，crizotinib，ceritinib，alectinib，brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China[J]. Front Public Health，2022，10：985834.
ZHU W T，ZHENG M M，XIA P P，et al. Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer：a Chinese healthcare system perspective[J]. Front Oncol，2023，13：1068463.
MISTRY R，MAY J R，SURI G，et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer：a U.S. payer perspective[J]. J Manag Care Spec Pharm，2018，24（6）：514-523.
LLOYD A，NAFEES B，NAREWSKA J，et al. Health state utilities for metastatic breast cancer[J]. Br J Cancer，2006，95（6）：683-690.
DARVISHI A，DAROUDI R，FAZAELI A A. Cost-utility analysis of palbociclib + letrozole and ribociclib + letrozole versus letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model[J]. Health Econ Rev，2023，13（1）：53.
COPE S，CHAN K，CAMPBELL H，et al. A comparison of alternative network meta-analysis methods in the pre-sence of nonproportional hazards：a case study in first-line advanced or metastatic renal cell carcinoma[J]. Value Health，2023，26（4）：465-476.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.